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Abstract 
Introduction: As frailty is associated with inflammation, biomarkers of inflammation may represent 
objective measures that could facilitate the identification of frailty. Glasgow prognostic score (GPS), 
combines C-reactive protein (CRP) and albumin, and is scored from 0-2 points. Higher score indicates 
a higher degree of inflammation. 
Objectives: To investigate whether (1) GPS is associated with frailty, (2) GPS could be used to screen 
for frailty, (3) IL-6 and TNF-α add to the accuracy of GPS as a screening tool, and (4) GPS adds 
prognostic information in frail older cancer patients. 
Methods:  Prospective, observational study of 255 patients ≥ 70 years with solid malignant tumours 
referred for medical cancer treatment. At baseline, frail patients were identified by a modified 
Geriatric Assessment (mGA), and blood samples were collected.  
Results: Mean age was 76.7 years, 49.8% were frail, and 56.1% had distant metastases. The 
proportion of frail patients increased with higher GPS (GPS zero: 43.2%, GPS one: 52.7%, GPS two: 
94.7%). GPS two was significantly associated with frailty (OR 18.5), independent of cancer type, 
stage, BMI and the use of anti-inflammatory drugs. The specificity of GPS was high (99%), but the 
sensitivity was low (14%). Frail patients with GPS two had poorer survival than patients with GPS 
zero-one. TNF-α and IL-6 did not improve the accuracy of GPS when screening for frailty. 
Conclusion: Frailty and GPS two are strongly associated, and GPS two is a significant prognostic 
factor in frail, older cancer patients.  The inflammatory biomarkers investigated are not suitable 




As the population grows older, the number of older patients with cancer increases (1). Due to large 
variations in health status, these patients represent a major challenge in clinical practice as some patients 
tolerate and benefit from standard cancer treatment whereas others have an increased risk of adverse 
reactions and questionable benefit of the therapy. Chronological age alone is a poor parameter for 
appropriate treatment decisions or estimation of life expectancy (1, 2).  
 Frailty is widely recognized as a state of increased vulnerability to stressors due to reduced 
functional reserves (2, 3), but there is no consensus on how it should be identified. A Geriatric 
Assessment (GA), which includes a systematic evaluation of comorbidity, cognitive and physical 
function, nutritional status, affective components and social situation (4), is considered the best clinical 
approach to assess vulnerability, and has frequently been used to identify frailty in oncology (5). To 
achieve a more targeted application of this relatively comprehensive procedure, a simple screening 
followed by a full assessment when deficits are detected, has been proposed (6). However, existing 
frailty screening tools have poor sensitivity and specificity (7), and there is a need to develop more 
precise or complementary methods to differentiate between fit and frail older patients with cancer. 
Biomarkers are attractive options as they are objectively measured and easily applicable in routine 
clinical practice. 
Ageing and inflammation are so closely related that the expression "inflammaging" has been 
coined (8). Many age-related conditions such as dementia, depression, and sarcopenia share an 
inflammatory pathogenesis (9). Hence, inflammation seems to play an important role in the development 
of frailty (10). Increased circulating levels of acute phase proteins such as C-reactive protein (CRP) and 
pro-inflammatory cytokines have been associated with both functional impairment and different 
measures of frailty (11-14).  However, CRP also tends to increase with age, body mass index (BMI) and 
sedentary lifestyle (15), as well as with infectious diseases and cancer. 
The negative impact of systemic inflammation in malignancies is well-known. The Glasgow 
prognostic score (GPS), for instance, which is based on the blood biomarkers of inflammation, CRP and 
albumin, is validated in more than 60 studies of cancer patients and predicts survival, weight and muscle 
loss (16).  
 The aims of this study were to investigate a) the association between GPS and frailty, b) if GPS 
could be used to screen for frailty, c) if the inflammatory markers Interleukin-6 (IL-6) and Tumor 
Necrosis Factor- α (TNF-α) add to the accuracy of GPS as a screening tool, and d) to explore if GPS 
adds prognostic information among frail older patients with cancer.  
 
Methods 
Design and patients:  
In this prospective, observational multicenter study, patients were consecutively recruited from eight 
outpatient cancer clinics at two university hospitals and six local hospitals in South East Norway from 
January 2013 until April 2015. The inclusion criteria were: age 70 years, histologically verified solid 
malignant tumor, referral to a specialist oncology service for a new cancer diagnosis or the first relapse 
after previous curative cancer treatment, and written informed consent. The patients were followed for 
two years or until death.  
The study was approved by the Regional Committee for Medical and Health Research Ethics 
South East Norway (2012/104) and registered at clinicaltrials.gov (NCT01742442). 
 
Assessments  
Pre-treatment baseline assessments included clinical and demographic data, a modified geriatric 
assessment, blood sampling, Eastern Cooperative Oncology Group (ECOG) performance status, cancer 
type, cancer stage, location of metastases, planned treatment, and whether treatment intent was curative 
or palliative.  
 
Modified Geriatric Assessment (mGA) 
Our Geriatric Assessment (GA) was performed by trained oncology nurses instead of a multidisciplinary 
team, and it did not contain all aspects of a comprehensive Geriatric Assessment (CGA) (1), which is 
why it is referred to as a modified GA (mGA). Eight different domains were assessed; comorbidity, 
activities of daily living (ADL), symptoms of depression, falls, polypharmacy, cognitive- and physical 
function, and nutritional status. 
 Patients were classified as frail according to a modification of the Balducci criteria(17) that 
has formerly been applied to identify frailty in older patients with cancer by Kristjansson et al. and 
Ommunndsen et al.  (18, 19).  In accordance with Balducci’s criteria and those used by Kristjansson 
and Ommundsen, our patients were categorized as frail if they reported one of the following deficits: 
Dependencies in ADL, significant comorbidity, or at least one or more geriatric syndromes (impaired 
cognitive function, depression, malnutrition, or falls). Furthermore, similar to Kristjansson et al, we 
included polypharmacy, which has also been proposed as a criterion by Winograd et al (20).  As a 
performance measure, which provides additional important information to the GA,  the Timed Up and 
Go (TUG) test was added to our mGA (21).  Although closely similar to the model applied by 
Kristjasson et al, our mGA as not been validated.  
The eight different domains were assessed by renowned and validated instruments (19), with 
defined cut-offs for impairments within each frailty domain (Table 1) (22-28). Table 1 summarizes how 
the different domains were assessed, which tools were used and which pre-defined cut-off values were 
chosen. 
   
Blood analyses  
Blood samples were collected at the time of inclusion. CRP and albumin were analyzed on a Cobas c501 
instrument (Roche Diagnostics, USA). EDTA-plasma samples were stored in a biobank at -80°C, and 
analyzed for TNF-α and IL-6 by an Immulite 1000 Instrument (Siemens Health Care Diagnostics Inc, 
Deerfield, IL, USA) using kits from the Immulite Immunoassay System. The analytic sensitivity of the 
IL-6 kit is 2 pg/ml, and 1.7 pg/ml for the TNF- kit. 
GPS 
The GPS is based on CRP and albumin. CRP ≤ 10mg/L and albumin ≥ 35 g/L = 0 points, CRP > 10mg/L 
or albumin < 35 g/L = 1 point, and CRP > 10mg/L and Albumin < 35g/L = 2 points. The higher the 
score, the higher the level of inflammation. A modified version of the GPS (mGPS) has been applied 
and tested in several studies (16, 29). The mGPS is also based on CRP and albumin, but 
hypoalbuminemia without an elevated CRP gives a score of 0.  
Statistics 
In our main, pre-specified analyses, GPS was treated as a categorical variable as appropriate, whereas 
IL-6 and TNF-α were used as continuous variables as generally recommended for the investigation of 
prognostic factors(30).The association between frailty and GPS was first investigated with a bivariate 
logistic regression model (Model-1a). To test how well the model discriminated between frail and non-
frail patients, the C-index was calculated. Further, a number of multiple logistic regression models were 
estimated. The models adjusting for either IL-6 (Model-2a) or TNF-α (Model-3a) or both (Model-4a) 
were estimated first. Then the four models were adjusted for diagnostic groups (breast-, prostate-, 
colorectal-, other gastrointestinal (GI), lung-and other cancer), stage of disease (localized disease, 
locally advanced or metastatic), BMI, and the use of anti-inflammatory drugs (NSAIDs and steroids) 
(Model 1b, 2b, 3b and 4b, respectively). The C-index was calculated for all multiple regression models 
and compared to the C-index for Model-1a. For explorative purposes, all analyses were repeated using 
the mGPS instead of the GPS, and with IL-6 and TNF-α categorized into quartiles. The latter was done 
to enable comparison to studies where this approach has been applied (31-33).  
 Finally, as another exploratory analysis, overall survival (OS) was compared between subgroups 
defined according to frailty status and GPS scores by Kaplan-Meier plots and log-rank test. Statistical 
significance was defined as p < 0.05. The statistical analyses were performed by SPSS v24 and StataSE 
v14.  
Results  
A total of 307 patients were included. One withdrew consent and 51 patients were excluded due to 
missing mGA data or blood samples (Figure 1). Thus, 255 patients were eligible for the present study, 
112 (43.9%) were women, and the mean age was 76.9 years. The most common cancers were colorectal 
(n= 69, 27.1%), lung (n= 55, 21.6%) and prostate cancer (n = 47, 18.4%) (Table 2). A total of 216 
patients (84.7%) were rated as ECOG PS 0-1, 143 (56.1%) had metastatic disease, and 127 (49.8%) 
were frail according to our mGA (Table 2). Among these, 68 (53,5% of all frail patients)  had deficits 
in one domain,  37 (29,1% ) in two and  22 (17,3%) in three or more domains.  
 
Inflammatory response  
The majority of patients had a low level of systemic inflammation according to the GPS; 162 patients 
(63.5%) presented with GPS zero, 74 (29.0%) with GPS one, whereas 19 (7.5%) had GPS two. The 
groups were comparable in terms of gender and age (45.1%, 41.9%, and 42.1% were women and mean 
age was 77.0, 76.8, and 75.8, for GPS zero, one, and two respectively). The frequency of metastatic 
disease and poor ECOG status increased with increasing GPS-score (Table 3). We also observed that 
the proportion of patients who received curative treatment was highest among those with GPS zero (GPS 
0: 44.4%, GPS 1: 2.7%, and GPS 2: 10.5%).   
 Of the 162 patients with GPS zero, 43.2% were frail, corresponding proportions for GPS one 
and GPS two were 52.7% and 94.7% (Table 3). Consequently, the sensitivity of GPS two as a screening 
tool for frailty was poor (only 14%), whereas the specificity was 99%.  
 In the overall study cohort, the mean value of IL-6 was 10.3 pg/ml (SD 19.6) and the mean value 
of TNF-α was 12.0 pg/ml (SD 6.4). For frail patients, mean IL-6 was 11.2 pg/ml (SD 15.4), and for the 
non-frail patients 9.3 pg/ml (SD 23.1). Mean (SD) for TNF-α were 12.3 pg/ml (5.6) and 11.7 pg/ml (7.1) 
for frail and non-frail patients, respectively. 
Main regression analyses 
Both bivariate (Table 4) and all multivariate (Table 5) regression analyses showed a highly significant 
association between GPS two and frailty. In the bivariate model (Model-1a), OR for being frail with 
GPS two was 23.7 (95% CI 3.1;181.5, p=0.002). After adjusting for diagnosis, stage of disease, BMI 
and the use of anti-inflammatory drugs (Model 1b, table 4), the OR was 18.5 (95% CI 2.3;148.2, 
p=0.006). The C-indices for the bivariate and multivariate model were 0.60 (95% CI 0.54;0.66), and 
0.68 (0.62;075), respectively (Table 4). The difference was statistically significant, indicating that the 
discrimination of frail versus non-frail patients improved by adding the clinical covariates.  
 When applied as continuous variables,IL-6 and TNF-α were not statistically significantly 
associated with frailty, neither in bivariate nor multivariate analyses. When adding IL-6, TNF-α, or both 
to the model including GPS only (Model 1a), the association between frailty and GPS two remained 
highly significant (Table 5), whereas the C-indices decreased (Table 5). However, this decrease, 
suggesting poorer models, was significant only for the model adding TNF-α to GPS.  
 Finally, the models including GPS and IL-6, TNF-α or both were also adjusted for diagnosis, 
stage of disease, BMI and the use of anti-inflammatory drugs (Models 2b, 3b and 4 b, Table 5). In all 
models, frailty and GPS two remained highly and significantly associated. The C-indices (Table 5) were 
all significantly higher for these models compared to those without clinical covariates, but not 
significantly different from the C-index for model 1b (adjusted for clinical covariates, not IL-6 and TNF-
α). Hence, the models improved by adding diagnosis, stage of disease, BMI and use of anti-inflammatory 
drugs, whereas the inflammatory markers, Il-6 and TNF, did not contribute to the discrimination 
between frail and non-frail patients.  
 The only statistically significant clinical covariate was the use of anti-inflammatory drugs. 
Interestingly, the use of such medication increased the odds for being frail (OR 2.3, 95% CI 1.1; 4.8, 
p=0.017) in Model-1b. 
  
 
Exploratory regression analyses 
Repeating the analyses using mGPS instead of GPS did not significantly change the results (data not 
shown). When running the analyses dividing IL-6 and TNF-α values into quartiles instead of using them 
as continuous variables, bivariate analyses showed a statistically significant association between frailty 
and the upper quartiles of both IL-6 and TNF-α. However, when adjusting for covariates, this association 
was no longer significant. Adding IL-6 and / or TNF-α values divided into quartiles did not significantly 
strengthen any of the GPS models.  
 
Survival 
We have previously shown that patients who were frail according to our mGA had inferior survival 
compared to non-frail patients (19). This was also the case in the present subset of patients. Frail patients 
had a median survival of 458 days, compared to 892 days for non-frail patients. We compared survival 
between non-frail patients with GPS zero-one, frail patients with GPS zero-one, and frail patients with 
GPS two, and found significant differences between these groups (p<0.001 for log-rank test), with a 
median survival of 898 days, 520 days and 245 days, respectively. Only one patient with GPS two was 
non-frail, and was excluded from the analysis.  
Discussion  
In this cohort of 255 older patients with a variety of cancer diagnoses, we found a strong association 
between high levels of inflammation (GPS two) and frailty, independent of cancer type, stage of disease, 
BMI, and the use of anti-inflammatory drugs. The higher the GPS score, the higher the probability of 
being frail. Most noticeable, 95% of the patients with GPS two were frail. We also found that frail 
patients with GPS two had poorer survival than frail patients with GPS zero or GPS one. To our 
knowledge, only one smaller study (n=52) has formerly investigated the relationship between frailty and 
GPS in older patients with cancer, and the results corroborate our findings. In that study, however, frailty 
was identified using the Edmonton Frail Scale (34), and mGPS was used instead of GPS. Their results 
demonstrated a significant correlation between mGPS and frailty. In our study, we found that the use of 
mGPS instead of GPS did not alter the results. The negative prognostic impact of a systemic 
inflammatory response, here demonstrated with increasing GPS score among frail patients, are in line 
with findings from a series of studies of cancer patients (15, 35). To the best of our knowledge, the 
potential ability of IL-6 or TNF-α to add information to frailty screening by means of GPS, has not 
formerly been investigated, but several studies have previously shown an association between frailty 
and inflammatory cytokines,, especially with respect to Il-6 (13, 36). Former results are, however, not 
entirely consistent (37), various factors have been taken into account in the analyses and various scaling 
methods for cytokines have been used. In our analyses, we adjusted for several other factors that might 
influence the level of inflammatory markers, such as BMI, the use of anti-inflammatory drugs, cancer 
diagnosis and stage of the disease. All patients were screened for fever at inclusion. Only five had fever, 
and it is unlikely that there were “false” high values of CRP, IL-6 or TNF-α due to infectious diseases. 
Furthermore, most former studies have been undertaken in non-cancer populations (14), or in patients 
with localized cancer (38). In our population, a large proportion had metastatic disease, and even if 
cancer diagnosis and stage of disease were controlled for, it is possible that the patients’ actual tumor 
volume influences the level of IL-6 (39, 40). A higher tumor burden might therefore be masking the 
impact IL-6 has on frailty. A higher detection level in our assay compared to other studies (41) may also 
have contributed to negative results. These considerations should be taken into account in the 
interpretation of our results. Thus, we conclude, as formerly advocated by Hubbard et al (14), that further 
studies are needed to clarify how biomarkers of inflammation correspond with frailty in various groups 
of cancer patients. Our results should also be interpreted in light of our frailty definition. As we 
defined impairment in only one domain as sufficient to be classified as frail, it is possible that patients 
who might be seen as pre-frail were included. However, our frailty definition was based on widely 
accepted indicators (19) assessed by renowned and validated methods, and on criteria closely similar to 
what has previously been applied (18, 43). Additionally, strict cut-offs were defined for impairments 
within each frailty domain (Table 1) (22-28), and we have formerly demonstrated that frailty according 
to our definition was independently predictive of survival (19). Hence, we believe that our definition is 
fully acceptable, although we cannot argue that it captures the true concept of frailty as no gold standard 
for identification exist. The heterogeneity of our study cohort is considered a strength. The different age, 
ECOG PS, cancer diagnoses and treatment intent, reflects the heterogeneity commonly seen in a daily 
oncology practice.   
 In summary, we have demonstrated a highly significant association between GPS two and 
frailty, with GPS two being highly specific for frailty. However, due to low sensitivity (14%), GPS alone 
cannot be recommended as a screening tool, and adding IL-6 and TNF-α  to the statistical model did not 
improve the sensitivity. Our study does, however, point towards an added prognostic value provided by 
GPS when added to mGA. By combining the two tools, we were able to identify a subgroup of frail 
patients with GPS two, with a particularly poor prognosis.    
 To conclude, we were not able to confirm that the biomarkers investigated can be used as a 
screening tool for frailty, but frailty and GPS two are strongly associated. Furthermore, our results 
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Table 1. The modified Geriatric Assessment (mGA) 
Domain   
Assessment 
method 
Range Rated by Cut-off value for frailty 
Nutritional 
status  




malnourished by nurse or 
self-reported weight loss 
≥10% the last 6 months. 





Patient >3 points 
Medications, 
polypharmacy 
ATCc 0-13 Nurse/ MD 
>7 regular medications 
(ointments & common 
vitamins excluded) 
Falls 
    Nurse 
Patient reports ≥2 falls the 






  Patient 
If reported yes a little/quite a 








Patient ≥7 points 
Physical 
function  








Nurse <24 points 
aPatient-generated Subjective Global Assessment, bThe Physical Health Section of the Older 
Americans’ Resources and Services Questionnaire, dAnatomical Therapeutic Chemical 
Classification System, dThe European Organisation for Research and Treatment of Cancer 
Quality of Life Core Questionnaire, eGeriatric depression scale, fTimed up and Go test, 






Table 2. Baseline characteristics 
 All Frail Non-frail 
 n (%) n (%) n (%) 
Total  255 (100)  127 (49.8) 128 (50.2) 
Age, mean 76.7 77.4 75.5 
Gender    
Female 112 (43.9) 58 (45.7) 54 (42.2) 
Diagnosis    
Breast 28 (11) 9 (7.1) 19 (14.8) 
Prostate 47 (18.4) 21 (16.5) 26 (20.3) 
Other GIa 30 (11.8) 16 (12.6) 14 (10.9) 
Lung 55 (21.6) 32 (25.2) 23 (18.0) 
Colorectal 69 (27.1) 33 (26) 36 (28.1) 
Other 26 (10.2) 16 (12.6) 10 (7.8) 
ECOGb    
0 110 (43.1) 38 (29.9) 72 (56.3) 
1 106 (41.6) 58 (45.7) 48 (37.8) 
2 34 (13.3) 26 (20.5) 8 (6.3) 
3 3 (1.2) 3 (2.4) - 
4 1 (0.4) 1 (0.8) - 
Missing 1 1 - 
Treatment    
Curative intentc 76 (29.8) 26 (20.5) 50 (39.1) 
Palliative chemotherapy 122 (47.8) 72 (56.7) 50 (39.1) 
Other palliative systemic 
cancer treatment 40 (15.7) 19 (15.0) 21 (16.4) 
Non-systemic palliative 
treatmentd 17 (6.7) 10 (7.9) 7 (5.5) 
Stage    
Localized 64 (25.1) 26 (20.5) 38 (29.7) 
Locally advanced 48 (18.8) 21 (16.5) 27 (21.1) 
Metastatic 143 (56.1) 80 (63.0) 63 (49.2) 
Use of anti- inflammatory drugs    
 44 (17.3) 28 (22.0) 16 (12.5) 
BMIe    
Mean 24.8 24.5 25.1 
aOther Gasto Intestinal, bEastern Cooperative Oncology Group performance status cReferred for 
neoadjuvant treatment, adjuvant treatment after curative surgery or curative radiotherapy d 




Table 3. Patients characteristic according to GPS  
  All GPSa0 GPS1 GPS2 
  n (%) n (%) n (%) n (%) 
Total 255 162 74 19 
Frail 127 (49.8) 70 (43.2) 39 (52.7) 18 (94.7) 
Non-frail 128 (50.2) 92 (56.8) 35 (47.3) 1 (5.3) 
ECOGb status  
  
 
0 110 (43.1) 90 (55.6) 18 (24.3) 2 (10.5) 
1 106 (41.6) 58 (35.8) 40 (54.3) 8 (42.1) 
2  34 (13.3) 11 (6.8) 16 (21.6) 7 (36.8) 
3  3 (1.2) 2 (1.3) - 1 (5.3) 
4  1 (0.4) - - 1 (5.3) 
Missing  1 (0.4) 1 (0.6) - - 
Treatment   
  
 
Curative intentc 76 (29.8) 72 (44.4) 2 (2.7) 2 (10.5) 
Palliative chemotherapy 122 (47.8) 52 (32.1) 55 (74.3) 15 (78.9) 
Other palliative systemic cancer 
treatment 
40 (15.7) 30 (18.5) 9 (12.2) 1 (5.3) 
Non-systemic palliative treatmentd 17 (6.7) 8 (4.9) 8 (10.8) 1 (5.3) 
Stage   
  
 
Localized 64 (25.1) 60 (37.0) 4 (5.4) - 
Locally advanced  48 (18.8) 30 (18.5) 15 (20.3) 3 (15.8) 
Metastatic 143 (56.1) 72 (44.4) 55 (74.3) 16 (84.2) 
BMIe   
 
 
Mean 24.8 25.1 24.4 24.1 
Anti-inflammatory drugs  44 (17.3) 28 (17.3) 13 (17.6) 3 (15.8) 
a Glasgow Prognostic Score, b Eastern Cooperative Oncology Group Performance Status,  c Referred 
for neoadjuvant treatment, adjuvant treatment after curative surgery or curative radiotherapy,  






Table 4. Results of bivariate logistic regression analysis (Model-1a) and multiple logistic 





Bivariate  Multivariate 
Model-1a   Model-1b  
OR (95% CI) p-value OR (95% CI) p-value  
GPSa           
0 1 - 1 - 
1 1.5 (0.8; 2.5) 0.176 1.1 (0.6; 2.1) 0.839 
2 23.7 (3.1; 181.5) 0.002 18.5 (2.3; 148.2) 0.006 
C-index  0.60 (0.54; 0.66) - 0.68 (0.62; 0.75)  0.014b 
Additional inflammatory 
markers 
    
IL6 1.0 (1.0; 1.0) 0.450  -   -  
TNF-α 1.0 (1.0; 1.1) 0.470  -  -  
Diagnosis         
Breast 1 - 1 - 
Prostate 1.7 (0.6; 4.5) 0.286 1.1 (0.4; 3.3) 0.837 
Other GI 2.4 (0.8; 7.0) 0.106 1.4 (0.4; 4.8) 0.586 
Lung 2.9 (1.1; 7.7) 0.027 1.7 (0.6; 5.3) 0.332 
Colorectal 1.9 (0.8; 4.9) 0.161 1.7 (0.6; 4.3) 0.301 
Other 3.4 (1.1; 10.4) 0.033 2.6 (0.7; 8.8) 0.139 
Stage         
Localized 1 - 1 - 
Locally advanced 1.1 (0.5; 2.4) 0.740 0.8 (0.3; 2.0) 0.678 
Metastatic 1.9 (1.0; 3.4) 0.043 1.4 (0.7; 2.8) 0.377 
BMIc 1.0 (0.9; 1.0) 0.253 1.0 (0.9; 1.0) 0.233 
Anti-inflammatory drugs 2.0 (1.0; 3.9) 0.046 2.3 (1.1; 4.8) 0.021 
a Glasgow Prognostic Score  
b p-value C-index model 1a vs C-index model 1b 
c Body mass Index 
Model 1a, bivariate model including GPS.  
13 
 
Table 5. Results of multiple logistic regression analyses 
Variable Model-2a Model-3a Model-4a Model-2b Model-3b Model-4b 
  OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
GPSa                   
0 1 - 1 - 1 - 1 - 1 - 1 - 
1 1.5 (0.9; 2.7) 0.147 1.5 (0.8; 2.6) 0.178 1.6 (0.9; 2.8) 0.151 1.2 (0.6; 2.3) 0.696 1.1 (0.6; 2.2) 0.768 1.2 (0.6; 2.4) 0.641 
2 25.8 (3.3; 203.5) 0.002 24.0 (3.1; 185.8) 0.002 26.0 (3.3; 206.5) 0.002 21.5 (2.6; 180.5) 0.005 19.3 (2.4; 156.4) 0.006 22.2 (2.6; 187.9) 0.004 
IL6b 1.0 (1.0; 1.0) 0.607     1.0 (1.0; 1.0) 0.614 1.0 (1.0; 1.0) 0.454     1.0 (1.0; 1.0) 0.465 
TNFαc     1.0 (1.0; 1.0) 0.882 1.0 (1.0; 1.0) 0.916     1.0 (0.9; 1.0) 0.637 1.0 (1.0; 1.0) 0.662 
Diagnosis                   
   Breast          1 - 1 - 1 - 
   Prostate          1.1 (0.4; 3.2) 0.869 1.1 (0.4; 3.3) 0.840 1.1 (0.4; 3.2) 0.870 
   Other GId          1.4 (0.4; 4.7) 0.635 1.4 (0.4; 4.8) 0.605 1.3 (0.4; 4.6) 0.651 
   Lung          1.8 (0.6; 5.4) 0.312 1.7 (0.6; 5.3) 0.337 1.8 (0.6; 5.4) 0.317 
   Colorectal          1.7 (0.6; 4.3) 0.306 1.6 (0.6 4.3) 0.320 1.6 (0.6; 4.2) 0.323 
   Other             2.5 (0.7; 8.5) 0.157 2.5 (0.7; 8.6) 0.152 2.4 (0.7; 8.4) 0.169 
Stage                   
   Localized          1 - 1 - 1 - 
   Locally 
adv.        
  0.6 (0.4; 2.1) 0.729 0.8 (0.4; 2.1) 0.709 0.9 (0.4; 2.1) 0.757 
   Metastatic             1.4 (0.7; 2.8) 0.371 1.4 (0.7; 2.9) 0.358 1.4 (0.7; 2.9) 0.354 




            2.4 (1.2; 5.1) 0.017 2.4 (1.1; 4.9) 0.020 2.5 (1.2; 5.1) 0.017 

























aGlasgow Prognostic Score, bInterleukin 6, cTumor necrosis factor alpha, dOther Gastro Intestinal, eBody Mass Index  
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